given this new information, its is not clear that the cardiovascular risk observed in approve makes vioxx unique in the class of similar drugs marketed in the us, mr kim explained. merck voluntarily stopped sales of vioxx on 30 september, a move which caused the firm's fourth quarter earnings to slide to 1.1bn 581m , from 1.4bn a year earlier.